Latent class trajectory modelling: impact of changes in model specification.

Body mass index cancer latent variable modelling statistical learning

Journal

American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030

Informations de publication

Date de publication:
2022
Historique:
received: 12 05 2022
accepted: 13 07 2022
entrez: 18 11 2022
pubmed: 19 11 2022
medline: 19 11 2022
Statut: epublish

Résumé

Latent class trajectory models (LCTMs) are often used to identify subgroups of patients that are clinically meaningful in terms of longitudinal exposure and outcome, e.g. drug response patterns. These models are increasingly applied in medicine and epidemiology. However, in many published studies, it is not clear whether the chosen models, where subgroups of patients are identified, represent real heterogeneity in the population, or whether any associations with clinically meaningful characteristics are accidental. In particular, we note an apparent over-reliance on lowest AIC or BIC values. While these are objective measures of goodness of fit, and can help identify the optimal number of subgroups, they are not sufficient on their own to fully evaluate a given trajectory model. Here we demonstrate how longitudinal latent class models can substantially change by making small modifications in model specification, and the impact of this on the relationship to clinical outcomes. We show that the predicted trajectory patterns and outcome probabilities differ when pre-specified cubic versus linear shapes are tested on the same data. However, both could be interpreted to be the "correct" model. We emphasise that LCTMs, like all unsupervised approaches, are hypotheses generating, and should not be directly implemented in clinical practice without significant testing and validation.

Identifiants

pubmed: 36398215
pmc: PMC9641469

Types de publication

Journal Article

Langues

eng

Pagination

7593-7606

Informations de copyright

AJTR Copyright © 2022.

Déclaration de conflit d'intérêts

None.

Références

Alzheimers Res Ther. 2018 Jan 15;10(1):4
pubmed: 29370871
PLoS One. 2016 Sep 16;11(9):e0162812
pubmed: 27636203
BMJ Open. 2018 Jul 7;8(7):e020683
pubmed: 29982203
J Abnorm Psychol. 2012 May;121(2):388-95
pubmed: 22250661
Eur J Epidemiol. 2016 Jun;31(6):583-92
pubmed: 26955830
Stat Methods Med Res. 2014 Feb;23(1):74-90
pubmed: 22517270
Arthritis Rheumatol. 2020 Oct;72(10):1632-1642
pubmed: 32475078
PLoS One. 2020 Jan 27;15(1):e0220232
pubmed: 31986142
PLoS Med. 2014 Feb 11;11(2):e1001602
pubmed: 24523667
Sci Signal. 2016 Jun 14;9(432):re6
pubmed: 27303057
Int J Cancer. 2016 May 15;138(10):2383-95
pubmed: 26704725
Br J Psychiatry. 1996 Jan;168(1):26-32
pubmed: 8770424
Aging Ment Health. 2020 Dec;24(12):2014-2021
pubmed: 31397178

Auteurs

Charlotte Watson (C)

Manchester Cancer Research Centre and NIHR Manchester Biomedical Research Centre Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester Manchester, UK.

Nophar Geifman (N)

School of Health Sciences, Faculty of Health and Medical Sciences, University of Surry Guildford, Surrey, UK.

Andrew G Renehan (AG)

Manchester Cancer Research Centre and NIHR Manchester Biomedical Research Centre Manchester, UK.
Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester Manchester, UK.

Classifications MeSH